FDA Grants Breakthrough Therapy Designation for...

By HEOR Staff Writer

June 1, 2026

The FDA has granted Breakthrough Therapy designation to calderasib (MK-1084) plus KEYTRUDA, signaling rapid progress in KRAS Inhibitor Therapy for newly diagnosed patients with advanced KRAS G12C-mutant non-small cell lung cancer and PD-L1 express...